Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

NCT07686068 is registered in ClinicalTrials.gov with VelaVigo Bio Inc as lead sponsor.

NCT NCT07686068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors
Lead sponsor
VelaVigo Bio Inc
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 18, 2026
Completion date
December 1, 2028
Enrollment
260 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

participants with advanced solid tumor malignancies